Opening of Public Offer and Publication of Research Report

Published: 26 November 2020

As previously announced to the market on 9 November 2020, cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU)(TruScreen or the Company) intends to undertake a capital raising initiative, by way of a public offer, to raise up to NZD$2 million (“Offer”) in conjunction with TruScreen’s application for the dual listing of its shares on the Australian Securities Exchange (ASX).The Offer opens today the 26 November 2020 and applications can be made through the online application portal at A copy of the registered Product Disclosure Statement in support of the Offer is available on the online application portal.

The Offer will close on 18 December 2020 (“Closing Date”).
An application has been made to the ASX for TruScreen to be admitted to the Official List of ASX as an ASX Foreign Exempt Listing and for quotation of the new shares to be offered in Australia on the ASX.

If TruScreen is admitted to the official list of ASX, then those Australian based investors in the Offer will have their Shares quoted on the ASX.

The Offer is conditional upon the ASX approving the admission of TruScreen to the Official List of the ASX as an ASX Foreign Exempt Listing and for the quotation of the new shares issued to Australian investors on the ASX on or before that Closing Date (as that date may be varied from time to time). In the event that this condition is not satisfied, then the Offer will not proceed, and all application moneys received by the Company will be refunded to investors in full and without deduction within 5 business days.

An issuer sponsored Research Report on TruScreen prepared by leading biotech analyst Stuart Roberts of Pitt Street Research Pty Limited was published by Pitt Street Research on 23 November 2020. A copy of the report is available on the Company’s website at